Browse Category

NASDAQ:TNXP News 23 November 2025 - 7 December 2025

TNXP Stock Today, 7 December 2025: Price, Latest News and 2026 Forecasts for Tonix Pharmaceuticals

TNXP Stock Today, 7 December 2025: Price, Latest News and 2026 Forecasts for Tonix Pharmaceuticals

Tonix Pharmaceuticals (NASDAQ: TNXP) has quietly turned into one of 2025’s wildest biotech stories: a tiny company that finally won U.S. FDA approval for a fibromyalgia drug after a 15‑year drought, launched it in the U.S., expanded the same molecule into major depressive disorder (MDD), and watched its stock price explode more than 10,000% over the last year. Tonix Pharmaceuticals Holding Corp.+2Fintel+2 As of the latest close on Friday, 5 December 2025, TNXP stock finished at $19.64, up 0.56% on the day, with after‑hours trading nudging it to $19.80. Over the past week, the share price jumped about 23%, and
Tonix Pharmaceuticals (TNXP) Stock Today, December 4, 2025: Tonmya Launch, Buyback and $400M ATM Define a Volatile Biotech Story

Tonix Pharmaceuticals (TNXP) Stock Today, December 4, 2025: Tonmya Launch, Buyback and $400M ATM Define a Volatile Biotech Story

As Tonix Pharmaceuticals transitions from clinical-stage hopeful to commercial biotech on the back of its new fibromyalgia drug Tonmya, Wall Street is split between blockbuster dreams and dilution fears. TNXP Stock on December 4, 2025: Price, Volume and Volatility Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) spent Thursday, December 4, 2025 trading around the high‑teens, with several data providers showing the stock near $19–20 per share during U.S. hours. MarketBeat cites a real‑time price of about $19.98, while CoinCodex shows $19.66, both up roughly 10–12% on the day. MarketBeat+1 That price puts Tonix’s market capitalization near $190 million, a tiny cap
Tonix Pharmaceuticals Stock on November 23, 2025: Tonmya Launch, Bigger Buyback, and a $400M ATM Shape the TNXP Trade

Tonix Pharmaceuticals Stock on November 23, 2025: Tonmya Launch, Bigger Buyback, and a $400M ATM Shape the TNXP Trade

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) heads into Sunday, November 23, 2025, with its first commercial fibromyalgia drug now on pharmacy shelves, a beefed‑up share repurchase program, and a sharply expanded at‑the‑market (ATM) equity facility. Together, those moves are redefining the risk‑reward profile of this small‑cap biotech just as investors focus on how quickly new product Tonmya can ramp. Tonix Pharmaceuticals Holding Corp.+2Investing.com+2 TNXP stock today: price, performance and valuation U.S. markets are closed today, but the latest full trading session for Tonix Pharmaceuticals stock (TNXP) was Friday, November 21, 2025: On the fundamentals side, MarketBeat data paint a classic

Stock Market Today

Broadcom Stock Gets a Google AI Spend Lift as Jefferies Sees 60% Upside

Broadcom Stock Gets a Google AI Spend Lift as Jefferies Sees 60% Upside

7 February 2026
Google raised its 2026 capital expenditure forecast to $175 billion–$185 billion, with most spending expected on data-center chips. Broadcom shares rose about 2% after the announcement, while Nvidia and AMD slipped. Jefferies reiterated a buy rating on Broadcom, maintaining a $500 price target, implying a 62% upside from Wednesday’s close.
No $2,000 IRS stimulus check is coming in February 2026 — but Trump’s tariff-check talk keeps the rumors alive

No $2,000 IRS stimulus check is coming in February 2026 — but Trump’s tariff-check talk keeps the rumors alive

7 February 2026
The IRS has not announced new federal stimulus payments for February 2026, and Congress has not approved fresh checks. Trump told NBC he is considering $2,000 tariff rebate checks but has not committed, saying any payout would likely come later in 2026. The IRS warns taxpayers to ignore texts and emails about “stimulus payments” and verify notices through official channels.
Go toTop